XML 32 R21.htm IDEA: XBRL DOCUMENT v3.25.3
Segment Information
 9 Months Ended
Sep. 30, 2025
Segment Reporting [Abstract]  
Segment Information Segment Information
The Company operates as one reportable segment in the United States, which includes all activities related to the development and commercialization of its DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases.
The Company's Chief Executive Officer (CEO) is its Chief Operating Decision Maker (CODM), responsible for allocating resources and assessing Company performance using aggregated financial information. Utilizing aggregated financial information enables the CODM to determine the most appropriate resource allocation across the organization, research and development projects or other initiatives consistent with the Company's corporate objectives. The CODM primarily uses total net loss as reported on the statements of operations and comprehensive loss to measure segment loss, supplemented by certain additional significant expense details reflected in the table below. The measure of segment assets is reported on the consolidated balance sheet as total assets.
Detailed information regarding the Company's single operating segment's revenues, expenses and operating loss are as follows:
Three Months Ended September 30,
20252024
Revenue from collaborative arrangement$— $— 
Less:
Research and development:
     INO-31073,352,458 7,009,169 
     INO-3112 and other Immuno-oncology1,574,238 1,726,382 
     Other programs (a)96,971 (1,119,600)
     Engineering and device-related4,323,775 5,602,688 
     Stock-based compensation302,249 590,211 
     Other unallocated expenses 3,683,638 4,924,734 
General and administrative7,877,126 8,613,895 
Total operating expenses21,210,455 27,347,479 
Interest income552,108 1,106,758 
Change in fair value of common stock warrant liabilities(22,515,730)— 
(Loss) gain on investment in affiliated entity(589,618)324,251 
Net unrealized gain on available-for-sale equity securities205,259 1,330,811 
Other expense, net(1,938,236)(579,819)
Net loss$(45,496,672)$(25,165,478)

Nine Months Ended September 30,
20252024
Revenue from collaborative arrangement$65,343 $100,762 
Less:
Research and development:
     INO-310710,790,120 25,697,828 
     INO-3112 and other Immuno-oncology4,327,081 5,309,964 
     Other programs (a)357,884 (292,372)
     Engineering and device-related14,470,247 14,192,615 
     Stock-based compensation1,177,331 2,240,800 
     Other unallocated expenses 12,822,975 15,586,056 
General and administrative25,465,208 29,395,232 
Total operating expenses69,410,846 92,130,123 
Interest income1,970,823 3,914,406 
Interest expense— (177,833)
Change in fair value of common stock warrant liabilities(20,680,868)— 
Gain (loss) on investment in affiliated entity881,886 (136,061)
Net unrealized gain on available-for-sale equity securities1,104,782 1,810,868 
Other expense, net(2,641,901)(1,254,466)
Net loss$(88,710,781)$(87,872,447)

(a) Net of contributions received from grant agreements and recorded as contra-research and development expense.